Clinuvel Pharmaceuticals (ASX:CUV) has announced the further expansion of its facilities in Singapore with new expanded laboratories to open on 1 July.
The company said the research and development capacity of its wholly-owned subsidiary, VALLAURIX, will be expanded through a new biological and analytical laboratory. It said it is also adding local personnel to its existing team and specialised technical laboratory equipment to further enhance the progress of its product pipeline.
The company also announced that the Singapore Economic Development Board (EDB) has backed VALLAURIX with a grant of up to A$547,000 over three years under their Research Incentive Scheme for Companies (RISC).
The grant is part of the Government of Singapore’s incentives to assist local businesses to develop their research capacity to advance high valued technologies.